Pyxis Oncology announced that it has received clearance for its two Investigational New Drug applications from the U.S. FDA to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer. Trials are expected to begin in early 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PYXS: